Medical AI Alliance
← Company Index
Medical DevicesKOSDAQ 228760Innovative Medical Device17 approvals

Genomictree Inc.

Official website

Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.

As of 2026-10-10, Genomictree Inc. has 1 MFDS Innovative Medical Device designation, 16 Korean MFDS device approvals, 35 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2000 and listed on KOSDAQ in 2019, the company is a cancer molecular diagnostics firm based on DNA methylation biomarkers. It received MFDS approval in 2018 and launched in 2019 its stool-based colorectal cancer test 'EarlyTect Colorectal Cancer (EarlyTect-C),' which uses the SDC2 gene methylation marker to deliver results within 8 hours. Consolidated 2025 revenue was KRW 3.76 billion, up 59.2% year-on-year, and the company is expanding overseas through its 2019 US subsidiary Promis Diagnostics and a 2020 technology license to Shandong Lukang Haoliyou in China.

Products & technology

  • EarlyTect-CStool-based colorectal cancer adjunctive diagnostic test
  • EarlyTect bladder/lung cancer diagnosticsBladder and lung cancer adjunctive diagnostic biomarkers

Regulatory approvals

data.go.kr

1 Innovative Medical Device designations · 2024 / 16 Korean MFDS device approvals · 2014–2026

  • InnovativeGT-BC2-12024-03-19
    Innovative Medical Device designation
  • MFDSIVD reagents for cancer related gene2026-01-08
    Product approval · Class 3체외 제허 26-19 호
  • MFDSSpecimen transport media2024-04-24
    Product approval · Class 1체외 제신 24-508 호
  • MFDSSpecimen transport media2023-01-04
    Product approval · Class 1체외 제신 23-13 호
  • MFDSSpecimen transport media2023-01-04
    Product approval · Class 1체외 제신 23-12 호
  • MFDSIVD reagents for extracting nucleic acids2021-08-26
    Product approval · Class 1체외 제신 21-1177 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-06-17
    Product approval · Class 3체외 제허 21-487 호
  • MFDSIVD reagents for extracting nucleic acids2021-04-07
    Product approval · Class 1체외 제신 21-468 호
  • MFDSSpecimen transport media2021-03-31
    Product approval · Class 1체외 제신 21-427 호
  • MFDSSpecimen transport media2020-08-20
    Product approval · Class 1체외 제신 20-1253 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-04-14
    Product approval · Class 3체외 제허 20-288 호
  • MFDSIVD reagents for cancer related gene2019-12-10
    Product approval · Class 3체외 제허 19-814 호
Show 5 more
  • MFDSSpecimen transport media2019-06-03
    Product approval · Class 1체외 제신 19-724 호
  • MFDSIVD reagents for cancer related gene2018-08-28
    Product approval · Class 3체외 제허 18-593 호
  • MFDSIVD reagents for extracting nucleic acids2018-07-02
    Product approval · Class 1체외 제신 18-792 호
  • MFDSIVD reagents for cancer related geneRevoked2018-01-03
    Product approval · Class 3체외 제허 18-6 호
  • MFDSOther reagents, classⅡ, for molecular diagnostics2014-04-14
    Product approval · Class 2체외 제허 14-854 호

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

SDC2 유전자 메틸화 마커 · 대장암 · 상용화(얼리텍-C) · Proprietary biomarker; delivers results within 8 hours (vs. ~26 hours for Cologuard)

대장암·방광암 보조진단 제품 미국 FDA 승인 · 대장암, 방광암 · 임상시험 및 승인 절차 진행 예정 · Clinical trials and approval process planned for US FDA approval alongside Korean MFDS approval

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 25 more publications

Patents

KIPRIS · applicant-matched
Show 150 more patents

AI reads

MAA server logs · IP-verified
91
Times AI engines pulled Genomictree Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

88
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

14
live 3
Last 7 days
71
live 3
Last 30 days
91
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot73
  • GoogleGoogleOther9
  • PerplexityPerplexityBot4
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Genomictree Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsMedical Devices

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BIONEERCORPORATION5 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

Gencurix Inc.4 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

LabGenomics. Co., Ltd.4 shared

KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.

SEEGENE, INC.4 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

Median Diagnostics Inc.3 shared

Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.

PCL. Inc3 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

RollingStone Co., Ltd.3 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

HLB PANAGENE Co., LTD.3 shared

Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.

Optipharm.CO.,LTD3 shared

Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.

GC Medical Science Corporation3 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

COSMAX BTI, INC.3 shared

Founded in 1992 and listed on KOSPI in 2006, COSMAX BTI is the COSMAX Group holding company overseeing health food and cosmetics affiliates.

SD BIOSENSOR INC.3 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition